Targeted Cancer Therapy - Global Strategic Business Report

The global market for Targeted Cancer Therapy was valued at US$16.1 Billion in 2025 and is projected to reach US$26.0 Billion by 2032, growing at a CAGR of 7.1% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Targeted Cancer Therapy Market - Key Trends & Drivers Summarized

Targeted cancer therapy, which attacks specific molecular drivers in tumors, now stands at the forefront of oncology innovation.

Advances in genomic profiling - especially next-generation sequencing - enable clinicians to match patients with therapies that inhibit specific genetic mutations. These treatments are increasingly preferred over generalized chemotherapy due to their ability to limit systemic toxicity and increase efficacy. The segment continues to grow as pharmaceutical companies develop drugs focused on narrow cancer subtypes, often using technologies like antibody-drug conjugates, kinase inhibitors, and radiopharmaceuticals. Public health bodies and NGOs are also supporting initiatives that encourage early detection and personalized treatment planning, contributing to broader therapy access and adoption.

What Technological Innovations Are Boosting Adoption?

Antibody-drug conjugates are redefining precision oncology by delivering cytotoxic agents directly to tumor cells, reducing off-target effects. Radiopharmaceuticals are also transforming treatment paradigms, particularly in solid tumors and metastatic conditions. Artificial intelligence is enabling more effective biomarker discovery, patient stratification, and trial design. In tandem, new diagnostic techniques such as liquid biopsies offer non-invasive, real-time monitoring of cancer progression. These are complemented by regulatory frameworks that support accelerated approvals and access programs, although challenges related to cost and equity remain prevalent in many regions.

The Growth in the Targeted Cancer Therapy Market Is Driven by Several Factors

The growth in the targeted cancer therapy market is driven by several factors related to genomics, therapeutic advancement, and system-wide adoption. The increasing global cancer burden is expanding demand for more personalized and effective solutions. Improved genomic screening capabilities have expanded the population eligible for precision therapies. Emerging modalities like radiopharmaceuticals and biologics are expanding treatment scope. Artificial intelligence and machine learning tools are improving treatment matching and drug development. Additionally, strategic collaborations and innovative payment models are helping overcome access barriers and drive adoption across diverse healthcare systems.

Report Scope

The report analyzes the Targeted Cancer Therapy market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Therapy Type (Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Other Therapy Types); Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications); End-Use (Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use, Academic & Research Institutions End-Use)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Hormone Therapy segment, which is expected to reach US$7.9 Billion by 2032 with a CAGR of a 8.8%. The Monoclonal Antibodies segment is also set to grow at 7.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $4.4 Billion in 2025, and China, forecasted to grow at an impressive 11.1% CAGR to reach $5.6 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Targeted Cancer Therapy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Targeted Cancer Therapy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Targeted Cancer Therapy Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Addex Therapeutics Ltd., Amgen Inc., AstraZeneca plc, Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Targeted Cancer Therapy market report include:

• AbbVie Inc.
• Addex Therapeutics Ltd.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BeOne Medicines (BeiGene)
• BioNTech SE
• Bristol-Myers Squibb Company
• Contera Pharma
• Daiichi Sankyo Co., Ltd.
• GSK plc.
• ImmunoGen, Inc.
• Merck & Co., Inc.
• Mirati Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Roche (F. Hoffmann-La Roche Ltd.)
• Sanofi
• Seagen, Inc.
• Takeda Pharmaceutical Co. Ltd.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.